/

AVXL

Anavex Life Sciences Corp.Pre-market

1.48−0.03 −1.99%USD

NasdaqGS · as of Oct 13, 16:00 ET · 15m delay

Open

1.53

Prev close

1.51

Day range

1.481.53

52-week range

1.449.50

Volume

1.19M1.21×

Mkt cap

137.19M

P/E ttm

—

Fwd P/E

-2.69

EPS ttm

-0.1400

Div yield

0.00%

Earnings

Aug 25, 2026

From 52w high

−84.42%

Price Chart

Yahoo Finance · delayed

AVXLOct 13, 2026O 1.53H 1.53L 1.48C 1.48−0.03 (−1.99%)Vol 1.19M

SMA 502.65
SMA 2003.27

1Y change −82.83% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

AVXL Anavex Life Sciences Corp. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −7.50%
1 month: −43.51%
3 months: −39.09%
6 months: −52.56%
Year to date: −58.43%
1 year: −82.83%

Valuation & ownership

Market cap: 137.19M
Enterprise value: 18.87M
P/E (ttm): —
Forward P/E: -2.69
PEG ratio: —
Price / book: 1.22
Price / sales (ttm): —
EV / EBITDA: —
EPS (ttm): -0.1400
EPS (forward): -0.5500
Beta (5y monthly): 1.17
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 92.70M
Float: 89.81M
Short % of float: 14.89%
Short ratio (days): 16.63
Held by insiders: 1.71%
Held by institutions: 40.50%
Avg volume (3m): 987.70K
50-day average: 2.68
200-day average: 3.28
52-week change: −82.83%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): oversold 18.4
vs 50-day SMA: −44.16%
vs 200-day SMA: −54.73%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 9.26%
Realised vol (20d, ann.): 70.7%
From 52-week high: −84.42%
From 52-week low: +2.78%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): —
Revenue growth (yoy): —
Earnings growth (yoy): —
Gross margin: 0.00%
Operating margin: 0.00%
Profit margin: 0.00%

DES

About Anavex Life Sciences Corp.

Yahoo Finance profile

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.

Sector: Healthcare
Industry: Biotechnology
Employees: 34
Headquarters: New York, NY, United States
Website: anavex.com
Officers: Ms. Sandra Boenisch CPA, CGA Principal Financial Officer & Treasurer

SEAS

Seasonality · AVXL

2007–2026 · monthly returns

Strongest month Feb +7.97%Weakest month Apr −5.04%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	32.0	-5.7	-30.7	8.8	-9.3	-14.5	6.2	1.8	-27.9	-26.7			−58.4%
2025	-13.7	-14.7	8.5	10.7	-20.7	22.4	22.6	-14.7	-7.7	-10.4	-51.9	-7.0	−66.9%
2024	-35.9	-13.9	-1.0	-28.3	11.2	3.9	61.0	-11.4	-5.6	16.5	42.9	13.5	+15.4%
2023	17.4	-12.4	-10.0	-5.0	13.5	-12.0	1.5	-4.2	-17.1	-14.8	29.2	29.1	+0.5%
2022	-24.6	-16.2	12.3	-30.2	6.1	9.9	2.5	-6.5	7.6	17.9	-27.5	5.0	−46.6%
2021	16.3	107.3	14.8	-19.2	3.1	83.6	-21.5	8.6	-7.9	4.4	3.5	-10.6	+221.1%
2020	10.4	33.2	-17.3	9.8	18.8	19.7	-14.2	0.5	7.3	29.7	-9.7	1.3	+108.5%
2019	18.6	15.7	42.5	-2.6	-2.7	16.6	-24.0	3.1	19.7	-13.9	-11.8	7.9	+66.0%
2018	-12.1	-16.6	16.9	-17.4	20.6	-4.7	3.1	-1.1	2.2	-11.7	-5.0	-31.9	−51.6%
2017	13.6	27.6	0.0	-1.9	2.8	-8.1	-23.7	9.4	-6.8	1.9	-10.0	-15.3	−18.7%
2016	-35.5	24.5	9.6	11.4	-18.7	37.6	-37.2	-20.3	18.6	-23.1	42.3	-0.3	−28.9%
2015	-5.9	9.2	11.1	37.4	37.9	12.5	102.2	48.4	4.4	87.6	-33.9	-20.3	+652.7%
2014	36.0	4.4	26.8	-15.6	-10.5	2.9	-25.1	-4.6	-26.4	0.5	8.1	-7.5	−26.0%
2013	-8.9	-12.5	11.9	-7.8	-1.5	-6.2	-16.7	22.2	6.4	-21.5	-12.7	-43.8	−68.4%
2012	38.5	3.6	-28.6	-35.2	54.3	-20.0	15.0	-5.2	-29.4	23.4	9.5	-24.0	−35.2%
2011	16.4	-10.8	-5.0	-12.5	4.4	-30.1	0.0	-22.6	9.6	-0.5	-38.1	1.7	−66.6%
2010	-1.9	20.9	23.1	-17.2	25.0	6.5	-11.8	11.5	18.8	-20.5	33.3	-14.7	+69.8%
2009	-0.8	-3.5	-19.7	22.0	10.2	-8.9	-12.2	20.9	1.9	-5.3	-9.2	-5.7	−17.3%
2008	2.7	-7.2	5.6	1.3	-7.1	-1.8	-0.6	-2.1	-57.5	25.2	-3.2	6.1	−50.5%
2007	14.8	12.9	2.6	4.5	1.1	-1.1	-0.3	-1.1	-1.4	2.7	2.9	36.0	+94.4%

INSD

Insider Activity · AVXL

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Sep 10, 2025	Missling Christopher UChief Executive Officer	Conversion of Exercise of derivative security at price 5.04 per share.	187.5K	$945.00K
Jun 4, 2025	Thomas Steffen PhdDirector	Conversion of Exercise of derivative security at price 1.76 per share.	50K	$88.00K
Mar 23, 2025	Missling Christopher UChief Executive Officer	Conversion of Exercise of derivative security at price 0.92 per share.	500K	$460.00K

AVXL

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

AVXL

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Anavex Life Sciences Corp.

Seasonality · AVXL

Insider Activity · AVXL

Congress Trades · AVXL

Investors Holding AVXL

Investors Holding AVXL

Congress Trades · AVXL

Insider Activity · AVXL

Seasonality · AVXL

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Anavex Life Sciences Corp.

Earnings & Dividends

News